The cardiovascular manifestations of rheumatic diseases

Current Opinion in Rheumatology

Volumn 18, Issue 2, 2006, Pages 135-140

  Goodson, Nicola J ^a,b   Solomon, Daniel H ^b  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Ankylosing spondylitis; Cardiovascular disease; Giant cell arteritis; Osteoarthritis; Rheumatic disease; Rheumatoid arthritis; Systemic lupus erythematosis; Systemic sclerosis

Indexed keywords

ANKYLOSING SPONDYLITIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC ARTHRITIS; CHRONIC INFLAMMATION; ENVIRONMENTAL FACTOR; GIANT CELL ARTERITIS; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MUSCULOSKELETAL FUNCTION; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; RHEUMATIC DISEASES;

EID: 33646708482     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000209424.77151.66     Document Type: Review

References (66)

1. Wolfe F, Mitchell DM, Sibley JT, Fries JF. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37:481-494.
2. Kvalvik AG. Mortality in rheumatoid arthritis. Rheumatol Eur 1996; 25:9-14.
3. Goodson NJ. Cardiac involvement in rheumatoid arthritis. In: Doria A, Pauletto P, editors. The heart in systemic autoimmune diseases, 1st ed. Amsterdam: Elsevier; 2004. pp. 121-144.
4. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52:402-411. This RA cohort study demonstrated that unrecognized myocardial infarction and sudden cardiac death were more common in RA patients.
5. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005; 64:1595-1601.
6. Bjornadal L, Brandt L, Klareskog L, Askling J. Impact of parental history on patients' cardiovascular mortality in patients with rheumatoid arthritis. Ann Rheum Dis; 25 October [Epub ahead of print].
7. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30:1196-1202.
8. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107:1303-1307.
9. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004; 63:952-955.
10. Warrington K, Kent P, Frye R, et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 2005; 7:984-991.
11. Douglas KMJ, Pace AV, Treharne GJ, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis (in press).
12. Chung CP, Oeser A, Raggi P, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005; 52:3045-3053.
13. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. The increased risk of ventricular diastolic dysfunction and congestive heart failure in patients with rheumatoid arthritis is independent of the duration of the disease. Semin Arthritis Rheum 2005; 35:132-133.
14. Crowson CS, Nicola PJ, Kremers HM, et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum 2005; 52:3039-3044.
15. Ahern M, Lever JV, Cosh J. Complete heart block in rheumatoid arthritis. Ann Rheum Dis 1983; 42:389-397.
16. Okada Y, Nakanishi I, Kajikawa K, Kawasaki S. An autopsy case of rheumatoid arthritis with an involvement of the cardiac conduction system. Japan Circ J 1983; 47:671-676.
17. Leden I, Eriksson A, Lilja B, et al. Autonomic nerve function in rheumatoid arthritis of varying severity. Scand J Rheumatol 1983; 12:166-170.
18. Toussirot E, Serratrice G, Valentin P. Autonomic nervous-system involvement in rheumatoid-arthritis: 50 cases. J Rheumatol 1993; 20:1508-1514.
19. Curtis BM, O'Keefe JH Jr. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc 2002; 77:45-54.
20. Symmons DPM, Bankhead CR, Harrison BJ, et al. Blood transfusion, smoking and obesity as risk factors for development of rheumatoid arthritis: results from a primary care based incident case-control study in Norfolk, England. Arthritis Rheum 1997; 40:1955-1961.
21. Gerli R, Sherer Y, Vaudo G, et al. Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci 2005; 281-290.
22. Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005; 32:435-442.
23. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44:2737-2745.
24. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004; 50:3450-3457.
25. Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165:1624-1629.
26. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005; 25:1776-1785.
27. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol 1999; 10:435-441.
28. Ridker PM. Connecting the role of C-reactive protein and statins in cardio-vascular disease. Clin Cardiol 2003; 26:1139-1144.
29. Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52:2293-2299.
30. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52:722-732.
31. Vaudo G, Marchesi S, Gerli R, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004; 63:31-35. This study demonstrates that even patients with low levels of RA disease activity have evidence of endothelial dysfunction measured using brachial flow mediated vasodilatation.
32. Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004; 33:65-72.
33. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173-1177.
34. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 2004; 110:1774-1779.
35. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106:2184-2187.
36. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004; 109:1718-1723.
37. Sarzi-Puttini P, Atzeni F, Doria A, et al. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus 2005; 14:780-784.
38. Konstantinopoulos PA, Lehmann DF. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005; 45:742-750.
39. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363:2015-2021. This randomized double-blind placebo-controlled trial of atorvastatin in RA revealed that atorvastatin had important antiinflammatory actions in RA that reduced disease activity as well as modifying CVD risk.
40. Peters MJ, van der Horst-Bruinsma I, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34:585-592.
41. Bergfeldt L. HLA-B27-associated cardiac disease. Ann Intern Med 1997; 127:621-629.
42. Symmons DPM, Goodson NJ, Cook MN, Watson DJ. Men with ankylosing spondylitis have an increased risk of myocardial infarction. Arthritis Rheum 2004; 50:1216.
43. Divecha H, Sattar N, Rumley A, et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 2005; 109:171-176.
44. Armstrong EP, Malone DC. The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents. Clin Therapeut 2003; 25:1-18.
45. Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003; 63:525-534.
46. Moder KGM, Miller TDM, Tazelaar HDM. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999; 74:275-284.
47. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924; 33:701.
48. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996; 335:1424-1430.
49. Wijetunga M, Rockson S. Myocarditis in systemic lupus erythematosus. Am J Med 2002; 113:419-423.
50. Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005; 257:485-495. A general review of the potential pathogenesis of accelerated atherosclerosis in SLE and RA.
51. Bjornadal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004; 31:713-719.
52. Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 2005; 19:823-838.
53. Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003; 48:3159-3167.
54. Toloza SM, Uribe AG, McGwin G Jr, et al., LUMINA Study Group: systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII: baseline predictors of vascular events. Arthritis Rheum 2004; 50:3947-3957.
55. Zampieri S, laccarino L, Ghirardello A, et al. Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Ann N Y Acad Sci 2005; 1051:351-361.
56. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96:254-259.
57. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2399-2406.
58. Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus: proposed guidelines for risk factor management. Rheumatology (Oxford) 2004; 43:7-12.
59. Coghlan JG, Denton CP. Cardiac involvement in scleroderma. In: Doria A, Pauletto P, editors. The heart in systemic autoimmune diseases, 1st ed. Amsterdam: Elsevier; 2004. pp. 189-195.
60. Uddhammar A, Eriksson AL, Nystrom L, et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002; 29:737-742.
61. Ray JG, Mamdani MM, Geerts WH. Giant cell arteritis and cardiovascular disease in older adults. Heart 2005; 91:324-328.
62. Duhaut P, Pinede L, Demolombe-Rague S, et al. Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes. Arthritis Rheum 1998; 41. pp. 1960-1965.
63. Kadam UT, Jordan K, Croft PR. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales. Ann Rheum Dis 2004; 63:408-414.
64. Singh G, Miller JD, Lee FH, et al. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care 2002; 8:383-391.
65. Conaghan PG, Vanharanta H, Dieppe PA. Is progressive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis 2005; 64:1539-1541.
66. Costenbader KH, Coblyn JS. Statin therapy in rheumatoid arthritis. South Med J 2005; 98:534-540.